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Metabolic disorders, particularly aberrations in lipid homeostasis, such as obesity, type 
2 diabetes mellitus, and hypertriglyceridemia often manifest together as the metabolic 
syndrome (MetS). Despite major advances in our understanding of the pathogenesis of 
these disorders, the prevalence of the MetS continues to rise. It is becoming increasingly 
apparent that intermediary metabolism within the central nervous system is a major con-
tributor to the regulation of systemic metabolism. In particular, lipid metabolism within 
the brain is tightly regulated to maintain neuronal structure and function and may signal 
nutrient status to modulate metabolism in key peripheral tissues such as the liver. There 
is now a growing body of evidence to suggest that fatty acid (FA) sensing in hypothalamic 
neurons via accumulation of FAs or FA metabolites may signal nutritional sufficiency 
and may decrease hepatic glucose production, lipogenesis, and VLDL-TG secretion. 
In addition, recent studies have highlighted the existence of liver-related neurons that 
have the potential to direct such signals through parasympathetic and sympathetic 
nervous system activity. However, to date whether these liver-related neurons are FA 
sensitive remain to be determined. The findings discussed in this review underscore the 
importance of the autonomic nervous system in the regulation of systemic metabolism 
and highlight the need for further research to determine the key features of FA neurons, 
which may serve as novel therapeutic targets for the treatment of metabolic disorders.
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iNTRODUCTiON
Metabolic disorders, particularly aberrations in lipid homeostasis, such as obesity, type 2 diabetes 
mellitus (T2D), non-alcoholic fatty liver disease, and hypertriglyceridemia, often manifest together 
as the metabolic syndrome (MetS) (1). Despite major advances in our understanding of the patho-
genesis of these disorders, the prevalence of the MetS continues to rise (2). Since MetS constitutes 
an increased risk to cardiovascular morbidity and mortality (3), a more detailed understanding of 
the common causes, and integration between these disorders of energy homeostasis, is necessary 
to identify novel therapeutic targets and interventions that may halt the development of severe 
metabolic disease.
It is becoming increasingly apparent that the central nervous system (CNS) is a major contributor 
to the regulation of systemic metabolism and lipid balance. In the CNS, the nutritional status of the 
body is constantly being surveyed and assessed by key energy-sensing regions of the brain, such as 
the hypothalamus. Key nuclei within the hypothalamus, such as the ventromedial nucleus (VMH), 
arcuate nucleus (ARC), dorsomedial hypothalamic nucleus (DMH), and the paraventricular nucleus 
2Bruce et al. Brain Lipids and Systemic Metabolism
Frontiers in Endocrinology | www.frontiersin.org April 2017 | Volume 8 | Article 60
(PVN), integrate signals to elicit peripheral responses, such as 
changes in feeding behavior, fuel mobilization, energy utilization, 
and energy storage (4). These nuclei detect both nutrients and 
nutritionally regulated endocrine factors, such as insulin (5), 
ghrelin (6), melanocortin (MC) (7), and leptin (8), in order to 
regulate feeding and energy balance. Here, in this review, we will 
focus on the mechanisms involved in lipid sensing in the brain 
and its emerging influence on systemic metabolism.
HOw DO LiPiDS eNTeR THe BRAiN?
Lipids and lipid intermediates are essential components of the 
structure and function of the brain. In fact, the brain has the 
second highest lipid content behind adipose tissue, and brain 
lipids constitute 50% of the brain dry weight (9). However, unlike 
adipose tissue, which largely stores FAs as triglycerides for sub-
sequent utilization and mobilization to other metabolic tissues, 
the brain is thought to mainly utilize acylated lipids to generate 
phospholipids for cell membranes (9). The FA composition of the 
brain is unique and is rich in long-chain polyunsaturated fatty 
acids (LC-PUFAs), particularly arachidonic acid (AA), eicosa-
pentaenoic acid, and docosahexaenoic acid (DHA). Although 
some FAs can be synthesized de novo, essential FAs must be 
transported into the brain from the systemic circulation. And 
contrary to previously held theories, recent data suggest that this 
is a dynamic process, with up to 8% of LC-PUFAs actively being 
turned over daily and being replaced by plasma-derived FAs 
(10). Indeed, a number of studies have shown that FAs are able 
to cross the blood–brain barrier (BBB) and enter neurons. For 
example, radiolabeled FAs that are injected into the carotid artery 
of rats can be traced to neuronal cells (10). In addition, brain 
perfusion studies in rats have shown that radiolabeled palmitate 
is readily incorporated into cerebral phospholipids and neutral 
lipids and has a similar rate of uptake when delivered via whole 
rat plasma or a synthetic saline containing physiological levels of 
albumin. This suggests that FAs cross the BBB and that albumin 
may be important in this process (11). Even though these studies 
convincingly demonstrate FA uptake, they do not address the 
mechanism of transport.
How FAs enter the brain remains an unanswered fundamental 
question. Although we cannot rule out the possibility that FAs 
could passively diffuse across the BBB, several studies highlight 
the role of FA transporters in this process. The membrane local-
ized FA transport proteins (FATP1 and FATP4) appear to be the 
predominant FA transport proteins expressed in the BBB based 
on human and mouse expression studies, whereas the FA trans-
locase/CD36 plays a prominent role in the transport of FAs across 
human brain microvessel endothelial cells (12). Furthermore, 
cytosolic-localized fatty acid-binding protein 5 has an important 
function in FA transport across cultured brain microvascular cells 
(13). Although still under active investigation, is it plausible that 
some transporters may also exhibit specificity toward particular 
FAs. For example, the major facilitator superfamily d 2 a, which 
is exclusively expressed in the endothelium of the BBB, has been 
shown to selectively transport DHA in the form of the partially 
hydrolyzed phospholipid, lysophosphatidylcholine, otherwise 
known as lysolecithin (14).
NeURONAL UPTAKe OF LiPiDS AND FAs
Neuronal uptake of FAs remains an important yet poorly under-
stood process. However, it is possible that once FAs have traversed 
the BBB, FA transporters may also play a key role in facilitating FA 
uptake into neurons. For example, dissociated neurons from the 
VMH express both FATP1 and CD36 (15). Specifically, important 
studies using fura-2 calcium imaging and fluorometric imaging 
plate reader membrane potential dye, in addition to pharma-
cological manipulations have shown that while neurons of the 
VMH and ARC respond to oleic acid (OA, C18:1 n-9) (15, 16), 
this response is lost when CD36 is depleted in the VMH using 
an adeno-associated viral (AAV) vector expressing CD36 short 
hairpin RNA (17). Since CD38 is an established gustatory lipid 
sensor, it is also plausible that other lipid sensors involved in 
the chemoreception of long-chain fatty acids (LCFAs)/omega-3 
fatty acids (ω-3 FAs), such as GPR120, are also involved in neu-
ronal lipid sensing. However, although GPR120 is functionally 
active in immortalized hypothalamic neurons and mediates the 
anti-inflammatory actions of the ω-3 FA, DHA (18), its role in 
neuronal lipid sensing in vivo has not been determined. In addi-
tion, FABP3, which is localized in neurons, facilitates brain AA 
but not palmitic acid (C16:0) uptake and trafficking into specific 
brain lipid pools (19).
It is also becoming more widely accepted that neurons may 
receive metabolic support from glial cells in a variety of forms. 
The “astrocyte–neuron lactate shuttle” has been postulated, 
whereby astrocytes metabolize glucose to release lactate, which 
is then taken up by the neuronally expressed monocarboxylate 
transporter, providing a supplemental energy source for neurons 
(20). Moreover, lipid metabolism in astrocytes plays a key role in 
FA sensing, since FA oxidation is thought to occur predominantly 
in the astrocyte rather than the neuron. When the levels of FAs 
are increased, as in the case of a high-fat diet (HFD), astrocyte-
mediated lipid oxidation results in elevated ketone levels in the 
brain. Conversely, changes in ketone abundance within energy-
sensing regions of the hypothalamus are able to modify energy 
homeostasis. Specifically, reduced ketone production within the 
VMH and ARC signals a decrease in HFD intake, and ketone pro-
duction can override glucose and FA sensing in VMH neurons 
(21, 22). Astrocytes may play a key role in the regulation of energy 
balance by sensing LCFAs as metabolic signals. For example, 
hypothalamic but not cortical astrocytes have a high capacity for 
the oxidation of LCFAs (23), and this flux may be AMP-activated 
protein kinase (AMPK) dependent. Both neurons of the VMH 
and astrocytes have been shown to express many of the FA trans-
porters, including FATP1, FATP4, and CD36. Most recently, the 
fatty acid bind protein 7 (FABP7) was shown to be important for 
astrocyte–neuron lipid homeostasis. Mice lacking FABP7 develop 
neuropsychiatric disorders such as schizophrenia, which may at 
least in part be due to aberrant dendritic spine morphology, and 
decreased spine density compared to WT mice (24). Moreover, 
transplantation of WT astrocytes into FABP7 KO mice partially 
attenuated cognitive impairments (24). Once transported into the 
cell, LCFAs are esterified by acyl-CoA-binding protein (ACBP), 
a protein that is ubiquitously expressed in tissues with high lipid 
turnover. Interestingly, ACBP is expressed in the hypothalamus 
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and may play a role in the LCFA sensing by hypothalamic astro-
cytes (25).
Astrocytes are also critical for the regulation of cholesterol 
homeostasis in the neuron. Cholesterol is an essential component 
of neuronal physiology during both development and adulthood 
and is independently tightly regulated in the brain, largely due to 
the existence of the BBB (26). Cholesterol depletion in neurons 
impairs vital functions, including synaptic vesicle exocytosis, 
neuronal activity, and neurotransmission and results in synap-
tic loss and neurodegeneration (27, 28). Clinically, deficits in 
cholesterol homeostasis in the CNS manifest as severe primary 
neurological disorders such as Neimann–Pick C disease and 
Parkinson’s disease (26). It is thought that astrocytes are a major 
site of lipoprotein synthesis and assembly in the brain (29). Of 
particular relevance is apolipoprotein E (ApoE), a 39-kDa protein 
that is highly expressed in the brain, surpassed only by hepatic 
ApoE production (30).
Apolipoprotein E-containing lipoproteins have been exten-
sively studied and are known to have several major functions. For 
example, ApoE-containing high-density lipoprotein (HDL)-like 
lipoproteins are secreted by astrocytes and are taken up into neu-
rons via low-density lipoprotein receptors. This transfer of key 
lipids and cholesterol facilitates axonal extension and neuronal 
survival and requires the presence of sphingomyelin in the ApoE-
containing lipoprotein particle (31, 32). ApoE does not only play 
a major role in glia-neuronal lipid metabolism but also acts as a 
ligand for multiple receptors in neurons, which interact with 
a number of downstream physiological processes (33). In par-
ticular, a number of recent studies have shown that brain ApoE 
is an important regulator of peripheral energy homeostasis. In 
rats, intracerebroventricular (ICV) ApoE injections significantly 
decreased food intake, whereas infusion of ApoE antiserum stim-
ulated feeding, therefore suggesting that ApoE may be important 
satiety factor in the hypothalamus (34). In support, exogenous 
ApoE treatment has been shown to activate phosphatidylinositol-
3-kinase (PI3K)/Akt signaling, and PI3K inhibition by LY294002 
attenuates both ApoE-induced signaling and satiation (35).
Apolipoprotein E has three major isoforms (ApoE2, ApoE3, 
and ApoE4), which have varying effects on lipid homeostasis and 
neuronal function. While both ApoE2 and ApoE3 preferentially 
associate with phospholipid rich HDL-like particles, ApoE4 
prefers large triglyceride-rich VLDL particles (36). Interestingly, 
ApoE4 has been repeatedly implicated in the pathogenesis of 
Alzheimer’s disease (AD) and may bind to the Aβ peptide leading 
to impair Aβ clearance (37). Current hypothesis suggests that the 
proteolytic cleavage products of ApoE4 may have a central role in 
AD pathology, since AD patients have markedly increased levels 
of these cleavage products compared to controls (38).
These findings suggest that lipoprotein metabolism in the CNS 
may be key to lipid homeostasis and nutrient sensing; however, 
to date, the molecular mechanisms underlying these processes 
remain largely unknown. Nonetheless, we have recently shown 
that lipoprotein lipase (LPL), the rate-limiting enzyme in the 
hydrolysis of lipoprotein-derived FAs, may facilitate the uptake of 
FAs into dissociated hypothalamic neurons (39). Moreover, mice 
with a specific neuronal LPL deficiency exhibit a defect in nutrient 
sensing and become hyperphagic, relatively inactive and obsessed 
compared to WT control mice (40). Interestingly, these mice are 
also polyunsaturated fatty acid (PUFA) deficient in the hypothala-
mus (40), and in the hippocampus, where LPL deficiency is also 
associated with alterations in learning and memory and synaptic 
function (41). In further support, a specific deletion of LPL in the 
hippocampus also leads to increased weight gain and decreased 
activity via a ceramide-dependent pathway (42). We have also 
shown that while mice lacking pan-neuronal LPL develop obesity, 
this obesity is not exacerbated on an HF diet, or rescued by a PUFA 
enriched diet, further highlighting the importance of LPL in lipid 
sensing and body weight regulation (43). These data highlight the 
potential role of LPL as a mechanistic link between brain lipid 
uptake, neuronal lipoprotein metabolism, and nutrient sensing; 
however, the precise role of LPL in lipid sensing in both neurons 
and glia requires further investigation.
HYPOTHALAMiC FA MeTABOLiSM
The evidence for facilitated FA uptake into neurons is limited, 
which may be due to the long-held view that neurons do not 
derive much of their energy supply from lipids. However, neu-
rons do express many molecular components of lipid catabolism 
pathways, suggesting that lipid utilization is a critical process to 
neuronal function. For example, neurons of the VMH express 
enzymes involved in the intracellular metabolism of FAs, includ-
ing long-chain acyl-CoA synthase (ACS), carnitine palmitoyl-
transferase-1a and 1c (CPT-1a and 1c), and uncoupling protein-2 
(UCP2), and enzymes involved in de novo lipogenesis, such as 
fatty acid synthase (FAS) (15). In addition, the nuclear recep-
tor peroxisome proliferator-activated receptor (PPARγ), a key 
factor in lipid metabolism that can be activated by endogenous 
lipid ligands to promote adipogenesis and insulin sensitivity, is 
predominantly expressed in neurons of the hypothalamus (44), 
including the ARC.
Activation of these intracellular metabolic pathways in 
hypothalamic cells in response to FAs provides further support 
of the role of lipid metabolism and sensing in hypothalamic 
neurons. For example, UCP2, which increases proton leak from 
the respiratory electron transport chain, may act as a metabolic 
switch from glucose metabolism to mitochondrial FA oxida-
tion in hypothalamic NPY/AgRP neurons during fasting (45). 
Interestingly, UCP2 likely mediates the actions of ghrelin, which 
is increased upon fasting, on the activation of NPY/AgRP neu-
rons. While ghrelin increases palmitate-induced mitochondrial 
respiration, this is not observed in UCP2−/− mice. Moreover, 
NPY/AgRP neurons of UCP2−/− mice do not show the ghrelin-
induced increase in mitochondrial biogenesis (45). In normal 
circumstances, increased FA oxidation increases reactive oxygen 
species (ROS), which are then scavenged by UCP2 via enhanced 
proton leak. However, in UCP2−/− mice, these ROS levels remain 
increased, supporting the hypothesis that ghrelin-triggered ROS 
production promotes UCP2 activity and mRNA expression to 
further promote ROS scavenging (45). These studies also sug-
gest that ROS may be involved in neuronal lipid metabolism 
and activation. In further support, suppression of ROS activates 
NPY/AgRP neurons to promote feeding, whereas activation of 
ROS activates proopiomelanocortin (POMC) neurons to reduce 
4Bruce et al. Brain Lipids and Systemic Metabolism
Frontiers in Endocrinology | www.frontiersin.org April 2017 | Volume 8 | Article 60
feeding. Although further studies are warranted, it is likely that 
neuronal ROS accumulation may intrinsically link neuronal 
substrate metabolism to feeding behavior and systemic energy 
balance (46).
AMP-activated protein kinase may also act as a cellular energy 
sensor within neurons to link neuronal lipid metabolism to 
systemic lipid metabolism and energy balance. AMPK is widely 
expressed in the ARC, PVN, and VMH of the hypothalamus and 
is able to sense intracellular energy status by the AMP/ATP ratio 
and the level of adipokines (e.g., leptin and ghrelin) [see Ref. (47) 
for a comprehensive review]. Activated AMPK responds to the 
cellular energy status and can switch cellular metabolism toward 
catabolic processes that produce ATP and away from anabolic 
processes that consume ATP (48). In response to glucose, hypo-
thalamic AMPK activity is inhibited leading to the activation of 
acetyl-CoA carboxylase (ACC) and the generation of malonyl-
CoA from glucose-derived acetyl-CoA, with downstream effects 
on food intake (described in more detail below) (49). Similar to 
peripheral tissues, malonyl-CoA is thought to inhibit CPT-1a and 
LCFA oxidation in the brain (49). Specifically, glucose inhibits 
palmitate oxidation via AMPK in hypothalamic neurons (23). 
Hypothalamic AMPK may also regulate downstream lipid 
metabolism through brown adipose tissue (BAT) thermogenesis. 
A number of recent studies have suggested that hypothalamic 
AMPK is involved in the autonomic regulation of BAT thermo-
genesis, specifically the SNS. For example, central administration 
of 3,3′,5′-triiodothyronine (T3) within the VMH stimulates a 
thermogenic response associated with decreased AMPK activ-
ity in the VMH and elevated sympathetic firing in BAT (50). 
Whether this effect is observed following neuronal glucose (or 
lipid) sensing remains to be seen. Nonetheless, this interesting 
topic has recently been reviewed in detail (51).
AMP-activated protein kinase also plays a key role in the 
hypothalamic response to leptin in the context of high-fat feed-
ing. While leptin results in reduced food intake and reduced 
hypothalamic AMPK activity, these effects were not observed in 
diet-induced obese mice (52). Hypothalamic phospho-AMPK is 
also modulated by the FA composition of the diet and is dependent 
on brain region and metabolic status (53). Interestingly, AMPK 
regulates the activity of a number of enzymes involved in the 
synthesis of complex lipids that are critical for optimal brain func-
tion and metabolism. For example, long-term AMPK stimulation 
blunted FA-mediated induction of serine palmitoyl transferase 
and the synthesis of ceramides de novo and has thus been shown 
to protect against fatty acid-mediated apoptosis in the astrocyte 
(54). Similarly, AMPK is highly expressed in neurons due to their 
high-energy demands and can promote neuronal survival during 
periods of glucose deprivation (55). Recently, neuronal AMPK 
has also been implicated in the pathogenesis of AD. AMPK 
activity can reduce sphingomyelin levels, inhibit Aβ generation, 
and reduce amyloid precursor protein (APP) distribution in lipid 
rafts, whereas deletion of AMPKα2 increases sphingomyelin and 
APP distribution in lipid rafts (56).
There is growing evidence to suggest that the accumulation 
of FA metabolites may signal nutrient status and thus may be 
critical to central lipid sensing, and the modulation of systemic 
metabolism. For example, upon entry into the neuron, LCFAs are 
esterified to LCFA-CoA by ACS. It is thought that this accumula-
tion of FA derived LCFA-CoA triggers a lipid-sensing mechanism 
to inhibit hepatic glucose production (HGP) and to maintain 
systemic glucose homeostasis (57). In support, direct inhibition 
of ACS in the hypothalamus disrupts the accumulation of hypo-
thalamic LCFA-CoA, and in turn disrupts the inhibitory effect 
on hepatic gluconeogenesis, resulting in dysregulated glucose 
production (58).
In metabolic tissues, intracellular LCFA-CoAs enter the mito-
chondria via CPT-1, where they are then subject to FA β-oxidation. 
Importantly, the liver isoform of CPT-1, CPT-1a, is prevalent in 
the hypothalamus, and inhibition of hypothalamic CPT-1a causes 
an increase in intracellular LCFA-CoA, which triggers a satiation 
signal, leading to reduced systemic glucose production and food 
intake (59). However, the neurocircuitry is complex since the role 
of CPT-1a may vary between hypothalamic nuclei. For example, 
VMH-selective overexpression of CPT-1a causes over feeding, 
a phenotype which can be reversed with the CPT-1 specific 
inhibitor etomoxir (60). In support, long-term overexpression of 
permanently activated CPT-1a using a viral AAV vector injected 
into the VMH of rats, leads to hyperghrelinemia, increased food 
intake, increased body weight, hyperglycemia, and insulin resist-
ance (61). In contrast, CPT-1a expression in the ARC does not 
have the same effect on the central regulation of feeding (60). 
Interestingly, the brain also expresses a neuron-specific isoform 
of CPT-1, CPT-1c, which is found in the endoplasmic reticulum 
(ER) of key energy-sensing nuclei of the hypothalamus (ARC) 
and has also been repeatedly implicated in the modulation of 
systemic metabolism (62–64). Specifically, CPT-1c KO mice have 
reduced body weight and food intake compared to control mice 
(62, 63). CPT-1c does not have a typical acyltransferase activity, 
and thus its precise molecular function is less well understood. 
Nonetheless, data from recent studies suggest that the orexigenic 
action of ghrelin is associated with increased hypothalamic 
(C18:0) ceramide levels, an effect that is blunted in CPT-1c KO 
mice (65). While the mechanism linking increased ceramide 
levels to energy balance remain an active area of research, recent 
studies have demonstrated that ceramides induce hypothalamic 
lipotoxicity and ER stress, which leads to sympathetic inhibition, 
reduced BAT thermogenesis, weight gain, and hepatic steatosis 
(66). In addition, recent metabolomic analysis of the brains of 
CPT-1c KO mice shows reduced levels of oxidized glutathione, 
suggesting that CPT-1c may play a role in neuronal oxidative 
metabolism (67). In addition, these mice show suppressed 
endocannabinoid levels, which offers an alternative yet consistent 
mechanism to account for the suppressed food intake observed 
in CPT-1c KO mice (67). In addition, to their established role in 
appetite modulation, endogenous endocannabinoids may serve 
as functional neuromodulatory lipids, derived from neuronal 
phospholipids, which once secreted undergo lipid catabolism 
within glial cells. A detailed description of endocannabinoid 
signaling is beyond the scope of this manuscript but has been 
previously reviewed in depth (68).
CPT-1 has been suggested to act downstream of malonyl-CoA 
in the hypothalamic control of feeding (60). This is particularly 
pertinent to FA metabolism in hypothalamic neurons since 
CPT-1 activity is inhibited by malonyl-CoA (69), and thus 
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elevated malonyl-CoA leads to an accumulation of LCFA-CoA 
(70), which has been previously referred to as a satiety signal. 
Indeed, manipulation of the key enzymes involved in malonyl-
CoA metabolism, including ACC, FAS, and malonyl-CoA decar-
boxylase (MCD), have all been shown to have major effects on 
food intake and peripheral metabolism (71). For example, ACC, 
which catalyzes the carboxylation of acetyl-CoA to malonyl-
CoA, is expressed in the ARC of the hypothalamus, where it is 
increased following central leptin treatment resulting in elevated 
malonyl-CoA and reduced food intake (72). Similarly, inhibition 
of FAS activity by central administration of the pharmacological 
FAS inhibitor C75 has been shown to reduce food intake (73) and 
to elevate malonyl-CoA levels (74). MCD, which is important 
for malonyl-CoA degradation, is also important for regulating 
lipid intermediates and systemic metabolism. Overexpression 
of MCD in the mediobasal hypothalamus (MBH) chronically 
reduces malonyl-CoA levels and causes rapid increases in food 
intake and weight gain (75). In addition, MBH expression 
depleted both malonyl-CoA and LCFA-CoA and was sufficient 
to induce hepatic insulin resistance in the presence of hyperlipi-
demia (75). These studies begin to highlight the importance of 
hypothalamic sensing of circulating lipids in the maintenance of 
hepatic metabolism and systemic glucose homeostasis. However, 
the physiological and molecular mechanisms that integrate 
the brain–liver axis remain unresolved and an active area of 
investigation.
HYPOTHALAMiC LiPiD SeNSiNG AND 
HePATiC MeTABOLiSM
Early studies by Obici and colleagues, where OA was adminis-
tered into the brain via ICV injection, were among the first to 
demonstrate the profound central effects of LCFAs on peripheral 
metabolism. Interestingly, the short chain FA octanoic acid (C8) 
did not have the same effect. Moreover, these studies showed that 
central OA administration could lower plasma insulin and glu-
cose levels under basal physiological conditions. To determine 
the mode of blood glucose reduction, pancreatic euglycemic 
clamps were performed during ICV infusion of OA. ICV OA 
administration leads to a marked decline in glucose production 
compared to basal levels (59). However, when clamps were 
performed in the presence of ICV OA and sulfonylurea, a potent 
inhibitor of neuronal KATP channels, the profound effect of central 
OA on HGP was blunted, suggesting that OA acutely enhances 
hepatic insulin action via the activation of KATP channels in the 
hypothalamus (59). Further studies support this notion and 
have shown that pharmacological activation of KATP channels in 
the hypothalamus (via hypothalamic diazoxide administration) 
suppresses HGP (76). These observations, taken together with 
the findings from CPT-1 inhibition studies, strongly suggest that 
the accumulation of LCFA-CoAs is able to suppress HGP (70). 
Recent studies have suggested that this system may actually be 
even more complex and have shown that the effect of LCFAs 
on hepatic metabolism may be FA specific. For example, while 
bilateral infusion of OA into the MBH results in a significant 
reduction in HGP, palmitic acid (PA, C16:0) has a lesser effect, 
and linoleic acid has no effect compared to vehicle control (LA, 
C18:2 n-6) (77). These data suggest that mono-unsaturated fatty 
acids are a more potent suppressor than saturated fatty acids or 
PUFAs; however, the mechanisms underlying these differential 
effects of FAs on hepatic glucose metabolism remain to be 
determined.
In addition to the central regulation of HGP, hypothalamic 
nutrient sensing may also be a key regulator of hepatic lipid 
homeostasis. The liver maintains lipid homeostasis through 
tightly coordinated synthesis and secretion of triglyceride-
rich lipoproteins (VLDL-TG), lipogenesis, and FA oxidation. 
Interestingly, infusion of the orexigenic neuropeptide Y directly 
into the third ventricle of the hypothalamus has been shown to 
increase hepatic VLDL-TG secretion, which may be part of the 
physiological response to fasting when lipids become the main 
energy source and NPY neurons in the ARC of the hypothalamus 
are activated (78). Thus, VLDL-TG secretion may be a response 
by the autonomic nervous system (ANS) to mobilize lipids during 
a period of relative nutrient deficiency. In addition, sympathetic 
denervation prevented the increase in the VLDL-TG secretion in 
the fasted state, whereas total denervation, or parasympathetic 
denervation did not, suggesting that the central regulation of 
hepatic lipid mobilization during fasting may be largely mediated 
through the sympathetic nervous system (78). In further support, 
sympathetic hepatic denervation also prevented the stimulatory 
effect of NPY on VLDL-TG secretion (78). This is in contrast to 
glucose sensing in the MBH (79), and glycine in the dorsal vagal 
complex (DVC) (80), which is thought to signal sufficient nutri-
ent status and inhibit VLDL-TG secretion, possibly through the 
parasympathetic nervous system.
In addition to NPY, a number of studies have also shown that 
MC expressing neurons of the hypothalamus may also regulate 
hepatic lipogenesis and TG metabolism. Central administration 
of MTII, a synthetic MC3/4 receptor agonist, has been shown 
to reduce hepatic lipogenic gene expression in mice (81) and 
decrease hepatic TG content in rats (82), suggesting that increased 
MC signaling can inhibit hepatic VLDL-TG production. In sup-
port of this notion, central administration of an MC3/4 receptor 
antagonist, markedly increased liver TG content in rats, strongly 
suggesting that hepatic lipogenesis was increased (7).
Melanin-concentrating hormone (MCH) is also involved in 
the neuronal circuits that modify autonomic outflow to the liver 
and white adipose tissue. MCH-deficient mice are hyperphagic 
and lean when fed a normal diet (83), are resistant to age asso-
ciated insulin resistance (84), and when fed an HFD they are 
resistant to obesity and hepatic steatosis (85). Recent key studies 
have also shown that genetic activation of MCH specifically 
in the LH triggers hepatic lipid accumulation and lipoprotein 
uptake (86).
This neurocircuitry is relevant to the pathogenesis of obesity, 
since numerous models of obesity and diabetes are character-
ized by elevated NPY. In a recent study, ICV administration 
of NPY or a selective NPY Y1 receptor agonist was shown to 
robustly elevate key genes involved in MUFA synthesis, such as 
stearol-CoA desatrate-1, and PL remodeling, such as ribosyla-
tion factor-1 (ARF-1) and lipin-1 (87). Importantly, these effects 
were attenuated following sympathetic denervation of the liver, 
FiGURe 1 | Schematic representation of the neuronal regulation of 
hepatic carbohydrate and lipid metabolism. Neurons of discrete 
hypothalamic nuclei including the paraventricular nucleus (PVN) and arcuate 
nucleus (ARC) within the mediobasal hypothalamus respond to neuronal 
inputs to regulate hepatic glucose and very low density lipoprotein (VLDL-TG) 
metabolism. The accumulation or application of long-chain fatty acids 
(LCFAs), such as oleic acid (OA), glucose, and melanocortin (MC) signaling 
act through the autonomic nervous system to signal nutritional plenty a 
reduced requirement for energy substrate mobilization, by inhibiting VLDL-TG 
secretion and hepatic glucose production (HGP). This is at least in part due 
to reduced stearol-CoA desatrate-1 (SCD1) expression. In contrast, 
hypothalamic NPY is indicative of hunger and nutritional deficiency and can 
increase energy substrate mobilization via an increase in VLDL-TG and SCD1 
expression and HGP. The features of these fatty acid and nutritionally 
sensitive neurons are unclear; however, pseudorabies virus-152 labeling 
supports the notion that liver-related neurons in the PVN exist and may be 
involved in this autonomic regulation of hepatic metabolism.
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supporting a model in which central NPY modifies hepatic 
PL and VLDL via the sympathetic signaling to the liver (87). 
Although these findings suggest that central lipid sensing may 
be implicated in the regulation of hepatic lipid homeostasis (see 
Figure 1), the direct mechanisms remain elusive. Nonetheless, 
a number of recent studies highlight the role of central FAs in 
hepatic lipid homeostasis. For example, central administration 
of PA resulted in impaired leptin signaling and pro-inflamma-
tory response in the MBH and PVN (88). Furthermore, this 
was coupled with blunted leptin-induced changes in hepatic 
gluconeogenesis, glucose transportation, and lipogenesis (88). 
In a recent report, Yue and colleagues have shown that infu-
sion of OA directly into the MBH activates a PKC-δ to KATP 
channel axis, which suppresses VLDL-TG secretion in rats (89). 
Moreover, this signaling requires DVC and hepatic innervation, 
highlighting a novel MBD-DVC neurocircuitry that mediates 
MBH FA sensing and hepatic lipid homeostasis (89). These find-
ings are one step closer to the development of novel therapies 
that lower VLDL-TG secretion and restore lipid homeostasis 
in metabolic disorders; however, there is considerably more 
to learn regarding differential function of other hypothalamic 
neurons and their role in the autonomic regulation of hepatic 
metabolism.
LiveR-ReLATeD NeURONS iN THe 
HYPOTHALAMUS
Recent findings support the existence of liver-related neurons in 
key hypothalamic nuclei; therefore, we can speculate that these 
liver-related neurons are the link between central lipid sensing 
and hepatic lipid metabolism. The control of hepatic functions 
by the ANS is well known. In general, beside the abovementioned 
examples, sympathetic stimulation of the liver enhances endog-
enous glucose production and glycogenolysis, while the parasym-
pathetic nerves are responsible for inhibiting glucose production 
and promoting glucose storage (90–92). Preganglionic neurons 
are located in the spinal cord and brainstem, respectively, and 
transmit the information through the sympathetic and parasym-
pathetic nerves. These autonomic motor neurons receive infor-
mation from preautonomic neurons, which are located in higher 
brain areas and crucial for integration of brain signals (93, 94). 
Therefore, identifying the location of liver-related neurons and 
determining their cellular and molecular properties would be 
crucial to the understanding of brain–liver circuit.
Within the hypothalamus, the ARC, VMH, DMH, LH, and 
PVN are well recognized for their involvement in the regulation of 
a variety of metabolic functions of the body, and in particular the 
control of hepatic metabolism (95–101). Electrical and chemical 
stimulation have been feasible methods to establish direct con-
nections between the hypothalamus and sympathetic neurons 
in the spinal cord or parasympathetic neurons in the brainstem 
and to demonstrate the importance of the autonomic control in 
hepatic functions (98, 102–105). On the other hand, establishing 
the location of premotor inputs to the sympathetic and parasym-
pathetic motor neurons has been more challenging. Anterograde 
and retrograde tracers in combination with histochemical studies 
provided valuable information on the connections between the 
brain and liver (106), and the development of retrograde viral 
tracers opened new avenues to dissect the brain–liver pathway. 
Currently, transsynaptic neurotropic viruses are very valu-
able tools for identification of synaptic connections and neural 
networks. Among the neurotropic viruses, pseudorabies viruses 
(PRVs) are often used for circuit analysis and revealing organiza-
tion of the nervous system (107–110). PRVs, such as PRV-152, an 
attenuated viral strain driving the expression of EGFP, are reliable 
and effective transsynaptic tracers, and numerous publications 
reported consistent organ-specific labeling of neurons (111–115). 
The spread of PRV-152 is strictly retrograde across synapses, and 
the virus is not capable of assembling in axons or glia; therefore, 
labeling of neurons not specific to the liver is unlikely, as has been 
shown (110, 116–118).
Polysynaptic neural connections between the brain and 
liver were identified in rodents using PRVs (118–120). PRV 
labeling was observed in the spinal cord of rats 3 days following 
inoculation, whereas at this time point no labeling was detected 
in parasympathetic nuclei (119). Labeled neurons in the dorsal 
motor nucleus of the vagus (DMV) were observed 4–5 days after 
inoculation of the liver. At this time point, liver-related neurons 
were also detected in the brainstem including the ventrolateral 
medulla, NTS, raphe pallidus, and few neurons were identified 
in the hypothalamic PVN and LH (119). Longer survival time 
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provided labeling of liver-related neurons in nuclei connected 
to the PVN including the medial preoptic area, anterior hypo-
thalamic area, and ARC. PRV-labeled cells were also present in 
the VMH, suprachiasmatic nuclei, central amygdala, and bed 
nucleus of stria terminalis (119). This study demonstrated that 
PRV provides reliable identification of polysynaptic sympathetic 
and parasympathetic pathways to the liver (113, 115, 118, 120).
Despite the identification of liver-related neurons in the CNS, 
labeling with PRV does not distinguish between sympathetic and 
parasympathetic liver-related neurons in higher brain areas. In 
order to identify sympathetic- or parasympathetic liver-related 
hypothalamic neurons in rats, PRV inoculation was combined 
with hepatic sympathectomy or parasympathectomy (121, 122). 
Following sympathetic denervation of the liver, parasympathetic 
liver-related neurons were identified in the brainstem DMV and 
nucleus ambiguus (122). Medium length survival time (~4 days) 
resulted in labeling of additional brainstem areas (e.g., NTS, 
area postrema) and hypothalamic nuclei including PVN, LH, 
DMH, ARC, and others (122). Retrograde labeling following 
parasympathectomy identified pre-sympathetic liver-related 
neurons in the PVN, medial preoptic area, anterior hypothalamic 
area, DMH, ARC, VMH, and SCN (121). These studies revealed 
that preautonomic PVN neurons project either to sympathetic 
or parasympathetic division, and the segregation of the neurons 
exists in other hypothalamic areas including LH and SCN 
suggesting functional specialization of preautonomic neurons 
controlling liver function. The segregation of the autonomic divi-
sions was also supported by the observation that stimulation of 
PVN resulted in hyperglycemia largely due to sympathetic activa-
tion of the liver (121). On the other hand, we have to note, that 
viral injection into peripheral organs causes infection of nerve 
terminals innervating both vascular and non-vascular tissues 
(123). PRV injected into the liver is taken up by nerve endings 
near hepatocytes and sinusoidal cells, and we cannot distinguish 
between neurons innervating liver function or hepatic vascula-
ture at the injection site. Therefore, it is likely that the PRV-labeled 
pre-sympathetic neurons contribute to both vasomotor and non-
vasomotor sympathetic innervation of the liver.
Our current knowledge regarding the role and cellular 
properties of liver-related hypothalamic neurons is somewhat 
limited. Earlier studies suggested that the VMH is involved in the 
sympathetic control of the liver, whereas the LH plays role in the 
parasympathetic control of the liver (91, 124, 125). The PVN was 
also shown as an important, integrative center for the regulation 
of sympathetic and parasympathetic pathways to the liver (121, 
126–128). Hypothalamic action of metabolic signals includ-
ing insulin, leptin, and FAs has been shown to control glucose 
homeostasis (58, 59, 76, 129–133); however, the cellular proper-
ties, the phenotype, or the involved neural circuits underlying the 
central control of hepatic functions are less defined.
Hypothalamic nuclei are heterogeneous containing differ-
ent types of neurons, which are able to control multiple organ 
systems; therefore, identification of pathway-related neurons is 
crucial. Our laboratory used the retrograde PRV tracing tech-
nique, discussed above, to identify liver-related neurons in the 
PVN and to reveal synaptic properties of liver-related neurons 
in control and hyperglycemic conditions (113). The studies 
determined that liver-related neurons receive transient receptor 
potential vanilloid type 1 (TRPV1) containing inputs. TRPV1 is a 
non-selective cation channel and has been linked to the develop-
ment and progression of type 1 diabetes mellitus and T2D (134), 
and recent reviews have discussed its role in diabetes mellitus 
and obesity in further detail (135, 136). The TRPV1-dependent 
excitation of liver-related PVN neurons was diminished in a 
hyperglycemic, insulin-deficient mouse model. Both in  vivo 
and in vitro insulin replacement restored the TRPV1-dependent 
excitatory neurotransmission via PI3-kinase, PKC, and/or TRPV1 
trafficking (113). Similarly, TRPV1 was shown to play role in the 
regulation of excitatory neurotransmission to motor neurons in 
the DMV and stomach-related neurons in the PVN (137, 138). 
Furthermore, potential interaction between leptin signaling and 
TRPV1 has been proposed in the brainstem (114). In addition, 
there is limited information about the neurochemical phenotype 
of liver-related neurons. A study by Stanley and coworkers identi-
fied liver-related hypothalamic neurons using PRV and showed 
that a subpopulation of liver-related neurons co-localized with 
oxytocin and CRH in the mouse PVN (118). In the LH, a subset 
of MCH and orexin neurons was shown to be liver related. In the 
ARC, a subpopulation of POMC neurons but not NPY-expressing 
neurons were labeled with PRV, indicating that they are part of 
the brain–liver pathway (118).
Despite the scientific advances in our understanding of liver-
related neurons, their precise role in the autonomic regulation 
of hepatic lipid metabolism remains to be determined. Although 
there is clear evidence that increased sympathetic outflow to the 
liver may increase VLDL-TG production, resulting in increased 
systemic FA availability, it remains to be determined whether the 
liver-related neurons of the hypothalamus are indeed FA sensitive, 
or indeed whether the FA-sensing neurons of the hypothalamus 
are liver related. It is plausible to suggest that liver-related neurons 
that direct hepatic triglyceride metabolism may express key lipid 
processing factors involved in lipid transport, e.g., CD36, FATP1 
and/or TG metabolism, e.g., LPL. However, a more detailed 
understanding of these fundamental autonomic processes is 
needed in order to identify novel therapeutic targets that may 
halt the development of lipid-related disorders.
SUMMARY, iMPLiCATiONS, AND 
iNTeRveNTiONS
The findings summarized in this review highlight the role of 
central lipid sensing in the regulation of systemic metabolism, 
including food intake, body weight, and hepatic glucose and 
lipid metabolism. Since increased HGP is a key factor in 
the development of glucose intolerance, understanding the 
neuronal mechanisms that drive the central regulation of 
HGP may be key to the development of novel therapeutic 
strategies that prevent hyperglycemia and the development of 
type 2 diabetes. In addition, our increased understanding of 
the hypothalamic control of TG metabolism highlights the 
potential utility of specifically modulating sympathetic nervous 
system activity toward the liver reduces VLDL-TG secretion 
and combat hypertriglyceridemia (139). The clinical relevance 
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of this strategy is highlighted by a recent north European 
human cohort, in which elevated sympathetic nervous system 
activity was associated with features of the MetS, such as 
elevated circulated VLDL-TG (140). While current interven-
tions for hypertriglyceridemia are aimed at reducing circulating 
FAs by increasing FA uptake from the plasma, an alternative 
approach to effectively lower TG could be though decreasing 
VLDL-TG production by the liver. This is the case with GLP-1 
receptor agonists, which have been shown to decrease both 
hepatic lipogenesis (141) and VLDL-TG production (142). 
Based on the literature outlined in this review, interventions 
targeting specific liver-related or FA-sensitive neurons in of 
the hypothalamus could have a similar impact on systemic 
metabolism, and we recommend that the identification of the 
features of these neuronal populations should be the subject 
of intensive research focus.
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